Skip to main content
NewslettersWatchlist

Viatris Inc(VTRS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low10.96
Day High11.24
Open:11.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Stocks Close Higher on Fed Rate Cut Optimism
Barchart
Stocks Rise on Fed Rate Cut Hopes
Barchart
Stocks Mixed as Weekly Jobless Claims Climb to an 8-1/2 Month High
Newswire.ca
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
Barchart
Stocks Settle Higher on Strength in Megacap Tech Stocks
Motley Fool
Is Viatris a Great Dividend Stock or Just a Value Trap?
Motley Fool
2 Dirt Cheap Dividend Stocks to Buy and Hold
Barchart
Stocks Slip Before the Open as Key U.S. Inflation Data Looms
Barchart
Stocks Finish Lower Ahead of Thursday’s Core PCE Deflator Report
Barchart
Stocks Decline Ahead of Thursday’s Key Inflation Report
The Globe and Mail
17 U.S. stocks that may benefit from eventual easing in interest rates
Motley Fool
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
Barchart
Stocks Settle Mixed as Bond Yields Decline
Barchart
Stocks Recover Early Losses After Bond Yields Slip
Barchart
Markets Today: Global Stocks Slide as Bond Yields Climb
PR Newswire
Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking
Motley Fool
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
PR Newswire
Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023
Motley Fool
2 Top Value Stocks to Buy in October
Motley Fool
2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip
Barchart
Stocks Settle Mixed as Big Tech Gains Despite Rising Bond Yields
Barchart
Stocks Mixed on Higher Bond Yields and Strength in Big Tech
PR Newswire
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
Motley Fool
Could Viatris Stock Help You Become a Millionaire?
Motley Fool
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
PR Newswire
Viatris Named to TIME's World's Best Companies 2023 List
Motley Fool
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Barchart
Markets Today: Stocks Weighed Down by Disappointing Chinese and European Economic News
PR Newswire
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
Motley Fool
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know
Motley Fool
Viatris Stock: Bear vs. Bull
Motley Fool
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris

Profile

Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.